AR003975A1 - Una preparacion farmaceutica para la deteccinn de una anormalidades del sistema nervioso central - Google Patents

Una preparacion farmaceutica para la deteccinn de una anormalidades del sistema nervioso central

Info

Publication number
AR003975A1
AR003975A1 ARP960103930A AR10393096A AR003975A1 AR 003975 A1 AR003975 A1 AR 003975A1 AR P960103930 A ARP960103930 A AR P960103930A AR 10393096 A AR10393096 A AR 10393096A AR 003975 A1 AR003975 A1 AR 003975A1
Authority
AR
Argentina
Prior art keywords
nervous system
central nervous
abnormalities
detection
pharmaceutical preparation
Prior art date
Application number
ARP960103930A
Other languages
English (en)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR003975A1 publication Critical patent/AR003975A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1206—Administration of radioactive gases, aerosols or breath tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Atmospheric Sciences (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se ofrece una sustancia de diagnóstico para anormalidades del sistema nervioso central que comprende una sustancia transmisora marcada del sistemanervioso central o un precursor marcado de la sustancia transmisora donde por lo menos unod e los átomos de carbono se reemplaza por un isótopo decarbono y que sirve para diagnosticar anormalidades del sistema nervioso central (por ejemplo, depresión, Mal de Alzheimer, esquizofrenia) mediantesu aplicación a un cuerpo vivo por víaora l o como inyección y el estudio del cambio en la cantidad de isótopo de carbono en la respiración del cuerpovivo. La sustancia transmisora del sistema nervioso central o su precursor son por lo menos uno del grupo catecolaminérgicas,colin érgicas yserotoninérgicas. Como catecolaminérgicas: fenilalanina, tirosina, dopamina, epifredina. Serotoninérgicas: triptofano.
ARP960103930A 1995-08-08 1996-08-09 Una preparacion farmaceutica para la deteccinn de una anormalidades del sistema nervioso central AR003975A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP20258095 1995-08-08
JP704396 1996-01-19

Publications (1)

Publication Number Publication Date
AR003975A1 true AR003975A1 (es) 1998-09-30

Family

ID=26341285

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103930A AR003975A1 (es) 1995-08-08 1996-08-09 Una preparacion farmaceutica para la deteccinn de una anormalidades del sistema nervioso central

Country Status (13)

Country Link
US (1) US5916537A (es)
EP (1) EP0781145B1 (es)
JP (1) JP3635346B2 (es)
AR (1) AR003975A1 (es)
AT (1) ATE245035T1 (es)
AU (1) AU6631296A (es)
CA (1) CA2201620C (es)
DE (1) DE69629097T2 (es)
DK (1) DK0781145T3 (es)
ES (1) ES2201190T3 (es)
MX (1) MX9702602A (es)
PT (1) PT781145E (es)
WO (1) WO1997005906A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764817B1 (en) * 1999-04-20 2004-07-20 Target Discovery, Inc. Methods for conducting metabolic analyses
DE60239552D1 (de) * 2001-10-24 2011-05-05 Univ California Messung der protein-syntheseraten bei menschen und in experimentellen systemen durch verwendung von isotopisch markiertem wasser
JP2005517904A (ja) 2002-02-12 2005-06-16 ザ リージェント オブ ザ ユニバーシティ オブ カリフォルニア 標識取り込みにより生物学的分子の生合成の割合を測定する非侵襲性の方法
US20060094057A1 (en) * 2002-07-30 2006-05-04 Maro K. Hellerstein Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry
AU2003268416A1 (en) * 2002-09-04 2004-03-29 The Regents Of The University Of California Methods for measuring rates of replication and death of nfectious microbial agents in an infected host organism
CA2498378C (en) * 2002-09-13 2013-12-17 The Regents Of The University Of California Methods for measuring rates of reverse cholesterol transport in vivo, as an index of anti-atherogenesis
US20070248540A1 (en) * 2002-09-16 2007-10-25 The Regents Of The University Of California Biochemical methods for measuring metabolic fitness of tissues or whole organisms
CA2504313C (en) * 2002-11-04 2012-01-17 Marc K. Hellerstein Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body
US7262020B2 (en) * 2003-07-03 2007-08-28 The Regents Of The University Of California Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
US20050202406A1 (en) 2003-11-25 2005-09-15 The Regents Of The University Of California Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
EP1708758A4 (en) * 2004-01-15 2008-04-02 Cedars Sinai Medical Center SYSTEM AND METHOD FOR EXPRESSION PROTEOMICS BASED ON ISOTOPIC RATIO MODIFICATION
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
AU2005222430A1 (en) * 2004-03-11 2005-09-22 The Regents Of University Of California Temporal or spatial characterization of biosynthetic events in living organisms by isotopic fingerprinting under conditions of imposed isotopic gradients
US20050238577A1 (en) * 2004-03-29 2005-10-27 The Regents Of The University Of California Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling
US20060183238A1 (en) * 2005-02-09 2006-08-17 Applera Corporation Amine-containing compound analysis methods
JP4118918B2 (ja) * 2005-02-28 2008-07-16 シャープ株式会社 信号品質評価装置、情報記録再生装置、信号品質評価方法、記録条件決定方法、信号品質評価プログラム、信号品質評価プログラムを記録したコンピュータ読み取り可能な記録媒体
TW200711660A (en) * 2005-06-10 2007-04-01 Univ California Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development
SI1898961T1 (sl) * 2005-06-30 2014-08-29 Otsuka America Pharmaceutical, Inc. Postopek za individualiziranje levodopa/karbidopa terapije ob uporabi dihalnega testa
US20110319699A1 (en) * 2009-03-11 2011-12-29 Electricite De France Carbonaceous radioactive waste treatment
WO2012120518A1 (en) * 2011-03-08 2012-09-13 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (pku)
EP2753707A4 (en) 2011-09-08 2015-03-04 Univ California MEASUREMENT OF METABOLIC FLOW, IMAGING AND MICROSCOPY
EP2788772B1 (en) 2011-12-07 2018-02-14 GlaxoSmithKline LLC Methods for determining total body skeletal muscle mass
US9134319B2 (en) 2013-03-15 2015-09-15 The Regents Of The University Of California Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo
CN109796329A (zh) * 2019-03-26 2019-05-24 上海化工研究院有限公司 一种13C标记α-氨基丁酸的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0828934B2 (ja) * 1984-07-31 1996-03-21 株式会社東芝 保護制御装置
US5320825A (en) * 1991-05-01 1994-06-14 Trustees Of The University Of Pennsylvania Serotonin reuptake inhibitors for S.P.E.C.T. imaging
JP2844503B2 (ja) * 1991-11-20 1999-01-06 東京瓦斯株式会社 ガス測定装置
US5386832A (en) * 1993-06-11 1995-02-07 New England Deaconess Hospital Liver function breath test using aromatic amino acids
US5707602A (en) * 1996-03-25 1998-01-13 Meretek Diagnostics Measurement of gastric emptying

Also Published As

Publication number Publication date
ATE245035T1 (de) 2003-08-15
PT781145E (pt) 2003-11-28
DE69629097T2 (de) 2004-03-18
CA2201620A1 (en) 1997-02-20
ES2201190T3 (es) 2004-03-16
EP0781145A1 (en) 1997-07-02
CA2201620C (en) 2007-01-09
AU6631296A (en) 1997-03-05
EP0781145B1 (en) 2003-07-16
JPH09257791A (ja) 1997-10-03
MX9702602A (es) 1997-07-31
US5916537A (en) 1999-06-29
DK0781145T3 (da) 2003-10-13
WO1997005906A2 (en) 1997-02-20
JP3635346B2 (ja) 2005-04-06
DE69629097D1 (de) 2003-08-21
WO1997005906A3 (en) 1997-05-29

Similar Documents

Publication Publication Date Title
AR003975A1 (es) Una preparacion farmaceutica para la deteccinn de una anormalidades del sistema nervioso central
Narendran et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users
LaLumiere et al. Glutamate release in the nucleus accumbens core is necessary for heroin seeking
Robertson et al. Octopamine and some related noncatecholic amines in invertebrate nervous systems
Bradberry et al. The anxiogenic β‐carboline FG 7142 selectively increases dopamine release in rat prefrontal cortex as measured by microdialysis
ATE364404T1 (de) Säurelabile und enzymatisch spaltbare farbstoffkonstrukte zur diagnostik mit nahinfrarotlicht und zur therapie
Caine et al. Effects of D3/D2 dopamine receptor agonists and antagonists on prepulse inhibition of acoustic startle in the rat
UY26066A1 (es) Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion
CY1111855T1 (el) Συσκευη εγχυτη φαρμακου με συστημα οδηγησης που διευκολυνει την επαναφορα
Guo et al. Allosteric modulation of sigma‐1 receptors elicits anti‐seizure activities
BR0113300A (pt) Composto ou um sal deste farmaceuticamente aceitável, composição farmacêutica, método para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, uso de um composto ou um sal, é, métodos para localização dos receptores de gabaa em uma amostra de tecido, de inibição da ligação de um composto de benzodiazepina a um receptor de gabaa, e para a alteração da atividade de transdutora de sinal dos receptores de gabaa
EE200000802A (et) Fibronektiini ED-B regiooni vastased antikehad, neid sisaldavad konjugaadid ja nende kasutamine kasvajate ning angiogeneesiga seotud haiguste diagnoosimisel ja ravis
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
CN103816538A (zh) 一种卟啉衍生物纳米复合物制剂及其应用
Zhang et al. Activation of noradrenergic terminals in the reticular thalamus delays arousal from propofol anesthesia in mice
Steele et al. D1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats
PT1029233E (pt) Medicao da concentracao de uma substancia
JP2020023508A (ja) ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
WO2004112567A3 (en) Methods, device and system for in vivo detection
Jakovljević et al. Seasonal influence on platelet 5-HT levels in patients with recurrent major depression and schizophrenia
TW200501978A (en) Use of FGF-18 in the diagnosis and treatment of memory disorders
Bastianetto et al. DTG-induced circling behaviour in rats may involve the interaction between σ sites and nigro-striatal dopaminergic pathways
Karoum et al. Estimation of the contribution of peripheral and central noradrenergic neurones to urinary 3-methoxy-4-hydroxyphenylglycol in the rat
Chen et al. Significance of glutamate and dopamine neurons in the ventral pallidum in the expression of behavioral sensitization to amphetamine
Engleman et al. Ethanol drinking experience attenuates (‐) sulpiride‐induced increases in extracellular dopamine levels in the nucleus accumbens of alcohol‐preferring (P) rats

Legal Events

Date Code Title Description
FC Refusal